左旋甲状腺素应用于慢性充血性心力衰竭伴低T_3综合征的有效性及安全性研究
|
摘要
目的探讨左旋甲状腺素应用于慢性充血性心力衰竭(CHF)伴低T3综合征的有效性及安全性。方法选取2011年6月—2013年12月在珠海市第二人民医院心内科确诊并住院的CHF伴低T3综合征患者132例,随机分为对照组(58例)和治疗组(74例)。对照组患者采用常规抗心力衰竭治疗,治疗组患者在常规抗心力衰竭治疗基础上加用左旋甲状腺素,4周为1个疗程,两组患者均治疗4个疗程。比较两组患者治疗前后甲状腺功能指标〔血清三碘甲状腺原氨酸(T3)、甲状腺素(T4)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)水平〕及心功能指标〔左心室舒张末期内径(LVDD)、左心室射血分数(LVEF)、心输出量(CO)、左心室舒张早期充盈峰值流速/舒张晚期充盈峰值流速(E/A)比值及血清脑钠肽(BNP)水平〕,并观察治疗期间不良反应情况。结果两组患者治疗前血清T3、T4、FT3、FT4水平及治疗前后血清TSH水平比较,差异均无统计学意义(P>0.05);治疗组患者治疗后血清T3、T4、FT3、FT4水平高于对照组(P<0.05)。治疗前两组患者LVDD、LVEF、CO、E/A比值及血清BNP水平比较,差异无统计学意义(P>0.05);治疗后治疗组患者LVDD和血清BNP水平低于对照组,LVEF、CO和E/A比值高于对照组(P<0.05)。治疗期间两组患者均未发生血栓栓塞现象及其他明显不良反应。结论左旋甲状腺素能有效改善CHF伴低T3综合征患者甲状腺功能及心功能,且无明显不良反应,有效性及安全性均较高。
Objective To investigate the effectiveness and safety of levothyroxine on chronic congestive heart failure complicated with low T3 syndrome. Methods From June 2011 to December 2013,a total of 132 chronic congestive heart failure patients complicated with low T3 syndrome were selected in the Department of Cardiology, the Second People' s Hospital of Zhuhai,and they were randomly divided into control group( n = 58) and treatment group( n = 74). Patients of control group were treated with conventional anti- heart failure medication,while patients of treatment group were given extra levothyroxine based on conventional anti- heart failure medication,4 weeks as a course; both groups treated for 4 courses. Thyroid function index( including serum levels of T3,T4,FT3,FT4 and TSH) and cardiac function index( including LVDD,LVEF,CO,E /A ratio and serum BNP level) were compared between the two groups,and the incidence of adverse reactions during treatment was observed. Results No statistically significant differences of serum levels of T3,T4,FT3,FT4 or TSH was found between the two groups before treatment( P > 0. 05); after treatment, serum levels of T3,T4,FT3 and FT4of treatment group were statistically significantly higher than those of control group( P < 0. 05),while no statistically significant difference of serum TSH level was found between the two groups( P > 0. 05). No statistically significant differences of LVDD,LVEF,CO,E / A ratio or serum BNP level was found between the two groups before treatment( P > 0. 05); after treatment,LVDD and serum BNP level of treatment group were statistically significantly lower than those of control group,while LVEF,CO and E / A ratio of treatment group were statistically significantly higher than those of control group( P < 0. 05). No one of the two groups occurred thromboembolism or other obvious adverse reactions during treatment. Conclusion Levothyroxine have good effectiveness and high safety in treating chronic congestive heart failure complicated with low T3 syndrome, can effectively improve the thyroid function and cardiac function without significant adverse reactions.
Objective To investigate the effectiveness and safety of levothyroxine on chronic congestive heart failure complicated with low T3 syndrome. Methods From June 2011 to December 2013,a total of 132 chronic congestive heart failure patients complicated with low T3 syndrome were selected in the Department of Cardiology, the Second People' s Hospital of Zhuhai,and they were randomly divided into control group( n = 58) and treatment group( n = 74). Patients of control group were treated with conventional anti- heart failure medication,while patients of treatment group were given extra levothyroxine based on conventional anti- heart failure medication,4 weeks as a course; both groups treated for 4 courses. Thyroid function index( including serum levels of T3,T4,FT3,FT4 and TSH) and cardiac function index( including LVDD,LVEF,CO,E /A ratio and serum BNP level) were compared between the two groups,and the incidence of adverse reactions during treatment was observed. Results No statistically significant differences of serum levels of T3,T4,FT3,FT4 or TSH was found between the two groups before treatment( P > 0. 05); after treatment, serum levels of T3,T4,FT3 and FT4of treatment group were statistically significantly higher than those of control group( P < 0. 05),while no statistically significant difference of serum TSH level was found between the two groups( P > 0. 05). No statistically significant differences of LVDD,LVEF,CO,E / A ratio or serum BNP level was found between the two groups before treatment( P > 0. 05); after treatment,LVDD and serum BNP level of treatment group were statistically significantly lower than those of control group,while LVEF,CO and E / A ratio of treatment group were statistically significantly higher than those of control group( P < 0. 05). No one of the two groups occurred thromboembolism or other obvious adverse reactions during treatment. Conclusion Levothyroxine have good effectiveness and high safety in treating chronic congestive heart failure complicated with low T3 syndrome, can effectively improve the thyroid function and cardiac function without significant adverse reactions.
引文
[1]陈绍稀,吕晶,虞意华,等.甲状腺激素对心力衰竭伴低T3综合征患者心功能影响的Meta分析[J].心脑血管病防治,2014,14(1):22-26.
[2]查克岚.小剂量甲状腺素对老年慢性心力衰竭伴低甲状腺激素水平患者心功能的影响观察[J].吉林医学,2014,35(6):1128-1130.
[3]梁书琴.浅谈心力衰竭与低T3综合征[J].中外健康文摘,2012,9(13):42-43.
[4]黄如训.临床医学综合征[M].广州:广东科技出版社,1988:775.
[5]史卫明,田才林,赵金龙.甲状腺激素水平与充血性心力衰竭的相关性以及小剂量甲状腺素的干预作用[J].心脑血管病防治,2010,10(5):333-335.
[6]曹芳芳,李艳芳.慢性心力衰竭的免疫调节治疗进展[J].中华老年心脑血管病杂志,2009,11(1):75.
[7]吴慧娟,郑贞苍,赵辉.左甲状腺素替代治疗充血性心力衰竭伴低T3综合征患者56例[J].全科医学临床与教育,2013,10(6):620-622.
[8]杨秀珍,杨秀丽,王鹏.充血性心力衰竭患者的甲状腺激素检测结果分析[J].中国临床实用医学,2007,1(4):23-24.
[9]李小元,徐仿成,陈先文.甲状腺素对急性脑梗死患者病情严重程度及预后的影响[J].卒中与神经疾病,2011,18(6):353-356.
[10]傅蓉,杨庆渝,李和莅.低T3综合征与重症急性胰腺炎预后的相关性研究[J].西部医学,2011,23(10):1940-1942.
[11]王永堂,高洁,曾琳,等.创伤后应激障碍与神经内分泌关系研究进展[J].人民军医,2011,54(5):377-378.
[12]毛继康,任爱勤.甲状腺激素治疗难治性心力衰竭伴低T3,低T4综合征[J].中国循证心血管医学杂志,2011,3(1):53-55.
[13]吴慧娟,郑贞苍,赵辉.左甲状腺素替代治疗充血性心力衰竭伴低T3综合征患者56例[J].全科医学临床与教育,2013,10(6):620-622.
[14]冯燕玲,黄冰生,李劲草,等.小剂量左旋甲状腺素对伴低T3综合征的慢性充血性心力衰竭患者心功能的影响[J].国际心血管病杂志,2014,41(2):127-130.
[15]陈春晓,林卫宇,林仁家.卡维地洛联合厄贝沙坦治疗慢性充血性心力衰竭的疗效观察[J].实用心脑肺血管病杂志,2014,22(4):47.
[2]查克岚.小剂量甲状腺素对老年慢性心力衰竭伴低甲状腺激素水平患者心功能的影响观察[J].吉林医学,2014,35(6):1128-1130.
[3]梁书琴.浅谈心力衰竭与低T3综合征[J].中外健康文摘,2012,9(13):42-43.
[4]黄如训.临床医学综合征[M].广州:广东科技出版社,1988:775.
[5]史卫明,田才林,赵金龙.甲状腺激素水平与充血性心力衰竭的相关性以及小剂量甲状腺素的干预作用[J].心脑血管病防治,2010,10(5):333-335.
[6]曹芳芳,李艳芳.慢性心力衰竭的免疫调节治疗进展[J].中华老年心脑血管病杂志,2009,11(1):75.
[7]吴慧娟,郑贞苍,赵辉.左甲状腺素替代治疗充血性心力衰竭伴低T3综合征患者56例[J].全科医学临床与教育,2013,10(6):620-622.
[8]杨秀珍,杨秀丽,王鹏.充血性心力衰竭患者的甲状腺激素检测结果分析[J].中国临床实用医学,2007,1(4):23-24.
[9]李小元,徐仿成,陈先文.甲状腺素对急性脑梗死患者病情严重程度及预后的影响[J].卒中与神经疾病,2011,18(6):353-356.
[10]傅蓉,杨庆渝,李和莅.低T3综合征与重症急性胰腺炎预后的相关性研究[J].西部医学,2011,23(10):1940-1942.
[11]王永堂,高洁,曾琳,等.创伤后应激障碍与神经内分泌关系研究进展[J].人民军医,2011,54(5):377-378.
[12]毛继康,任爱勤.甲状腺激素治疗难治性心力衰竭伴低T3,低T4综合征[J].中国循证心血管医学杂志,2011,3(1):53-55.
[13]吴慧娟,郑贞苍,赵辉.左甲状腺素替代治疗充血性心力衰竭伴低T3综合征患者56例[J].全科医学临床与教育,2013,10(6):620-622.
[14]冯燕玲,黄冰生,李劲草,等.小剂量左旋甲状腺素对伴低T3综合征的慢性充血性心力衰竭患者心功能的影响[J].国际心血管病杂志,2014,41(2):127-130.
[15]陈春晓,林卫宇,林仁家.卡维地洛联合厄贝沙坦治疗慢性充血性心力衰竭的疗效观察[J].实用心脑肺血管病杂志,2014,22(4):47.